Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested higher clinical responses and differentiation from competitors [4]. - Allegations state that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a specific emphasis on dermatology and rheumatology [1]. Class Action Details - The class action was filed on behalf of all investors who purchased or acquired MoonLake's common stock during the class period from March 10, 2024, to September 29, 2025 [1]. - The lawsuit claims that the company failed to disclose critical information regarding the differences between its drug SLK and monoclonal antibodies, including the lack of superior clinical benefits and efficacy [3]. Allegations Against the Company - The complaint outlines several key allegations: 1. SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. 2. SLK's unique Nanobody structure does not provide a clinical advantage over BIMZELX's monoclonal structure [3]. 3. The supposed increased tissue penetration of SLK does not correlate with improved clinical efficacy [3]. 4. The company lacked a reasonable basis for its positive claims regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which indicated that SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers to the court by December 15, 2025, to serve as lead plaintiff [5]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [5]. Legal Representation - Robbins LLP is leading the class action and operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [6].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases driven by cytokines IL-17A and IL-17F [3]. Trial Results and Market Reaction - The Phase 3 trials for SLK revealed that only one of the two trials achieved statistical significance, with results showing substantially lower efficacy compared to the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, or about 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK's Nanobody structure over traditional monoclonal antibodies [5]. - Specific allegations include misleading claims about SLK's potential clinical benefits and the distinction between Nanobodies and monoclonal antibodies [5]. Legal Proceedings - The class action lawsuit is focused on the propriety of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3]. - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action securities lawsuit due to alleged securities fraud impacting investors between March 10, 2024, and September 29, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive claims made about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements [3]. - Key allegations include that SLK and BIMZELX share the same molecular targets, and SLK's unique Nanobody structure does not provide superior clinical benefits over BIMZELX [3]. - It is also claimed that SLK's supposed increased tissue penetration does not translate to clinical efficacy, indicating a lack of reasonable basis for positive statements regarding SLK's superiority [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is December 15, 2025, and there is no cost or obligation to participate [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices [5].

Core Viewpoint - MoonLake Immunotherapeutics faces a class action lawsuit following disappointing Phase 3 trial results for its drug candidate sonelokimab, which failed to demonstrate efficacy compared to a competitor's product, leading to a significant drop in stock price [2][3]. Company Overview - MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing innovative therapies, particularly in the field of immunotherapy [1]. Legal Proceedings - A class action lawsuit has been filed against MoonLake Immunotherapeutics, with a deadline of December 15, 2025, for shareholders to file a lead plaintiff motion [1][4]. - The lawsuit alleges that the company made materially false and misleading statements regarding its drug candidate sonelokimab and failed to disclose critical information about its efficacy compared to competitors [3]. Financial Impact - Following the announcement of the Phase 3 trial results on September 28, 2025, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [2].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for potential securities fraud and unlawful business practices following disappointing trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by Pomerantz LLP, which is known for its expertise in corporate and securities class litigation [5]. - Investors who purchased MoonLake securities during the Class Period have until December 15, 2025, to request appointment as Lead Plaintiff [2]. Group 2: Company Performance - On September 28, 2025, MoonLake reported unsatisfactory results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest improvements compared to placebo [4]. - Following the announcement of these results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [4].

Core Points - A securities fraud class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of the Securities Exchange Act of 1934 [3][4] - The lawsuit claims that the company made misrepresentations regarding its drug candidate, sonelokimab (SLK), which was marketed as superior to competing monoclonal antibody drugs [4] Summary by Sections Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3] - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, with no fees or expenses required from shareholders [5] Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6]

Core Viewpoint - MoonLake Immunotherapeutics faced a significant decline in share price following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a securities class action lawsuit alleging misleading statements about the drug's efficacy and trial design [1][2][6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with the efficacy of SLK being substantially lower than that of the competitor's FDA-approved product, BIMZELX [6]. - Following the announcement on September 28, 2025, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Statements - The lawsuit claims that MoonLake made false and misleading statements regarding SLK's advantages over BIMZELX, including assertions about superior efficacy and the unique benefits of its Nanobody structure [5][6]. - Specific allegations include misleading information about the clinical benefits of SLK compared to traditional monoclonal antibodies and the expected clinical efficacy based on its structural advantages [5]. Legal Proceedings - A securities class action has been filed against MoonLake, with a focus on the company's statements about SLK's trial design and efficacy data [1][3]. - The lead plaintiff deadline for the class action is set for December 15, 2025, and the firm Hagens Berman is actively seeking investors who suffered losses to participate in the lawsuit [3][6].